Skip Navigation

Annals of Oncology 2006 17(6):883-884; doi:10.1093/annonc/mdl099
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Armitage, J. O.
Right arrow Articles by Loberiza, F. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armitage, J. O.
Right arrow Articles by Loberiza, F. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

editorial

Is there a place for routine imaging for patients in complete remission from aggressive lymphoma?

J. O. Armitage* and F. R. Loberiza

University of Nebraska Medical Center, Omaha, NE, USA

* (E-mail: eryan@unmc.edu)

The first 10% of the full text of this article appears below.

Routine imaging of patients with aggressive lymphoma in complete remission is standard practice in most of the United States. The timing (i.e. every 6 months or every year), the duration (i.e. usually for 3–5 years) and the type of image performed (i.e. CT scan, PET scan or both) vary among clinicians. However, these studies are often routinely performed by academic oncologists and private practitioners. In this issue of the Annals, Liedtke et al. describe 108 patients with relapsed aggressive non-Hodgkin's lymphoma who were treated with ifosfamide, carboplatin and etoposide (ICE) followed by an autologous hematopoietic stem cell transplant in responding patients [1Go]. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
J. O. Armitage
How I treat patients with diffuse large B-cell lymphoma
Blood, July 1, 2007; 110(1): 29 - 36.
[Full Text] [PDF]